IMCB

IMCB (Gemabank) is a medical company and market leader among stem cell banks in Russia. It offers services in collection, isolation, cryopreservation and storage of PC ICs. It occupies about 44% of the Russian market at the end of 2018 by the number of samples in storage.
IMCB stock price chart
-4%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

IMCB balance sheet

Report period2017 2018 2019 2020 2021
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

IMCB cash flows

Report period2017 2018 2019 2020 2021
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

IMCB multipliers

Report period2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

IMCB profitability

Report period2017 2018 2019 2020 2021
ROA
ROE
ROS
EBITDA Margin
Operating margin
IMCB assets
IMCB cash flows
IMCB dividends
9.3%

IMCB shares

TickerNameTypeNominal valueISINPrice
GEMA:RMIMCBCommon shareRUB 0.1RU000A100GC7RUB 702

IMCB bonds

NameIssue sizePriceYield
IMCB JSC BO-P01-0130,000 pcs.RUB 99.9910.44%

IMCB expected events

DateTypeNoteSource
16.06.2022 10:00
Dividends
The last day of purchase for receiving dividends RUB 18 per common share for 2021.Pictogram of www.e-disclosure.ru  www.e-disclosure.ru
Share capital structure of IMCB
IMCB news
06.05.2022
Board of Directors of IMCB recommended that dividends be paid for 2021 in the amount of ₽18 per ordinary share. The last day of the purchase of securities to receive dividends is June 16, 2022. Dividend yield may amount to 2.5%.
06.05.2022
IMCB's RAS net income for 3 months of 2022 was ₽34.323 million, down 7.8% from ₽37.234 million in the previous year. Revenue increased 1.9% to ₽65.584 million versus ₽64.345 million a year earlier.
15.04.2022
IMCB's IFRS net income for 2021 was ₽136.5 million, up 11.2% from ₽122.774 million in the previous year. Revenue increased 9.6% to ₽265.889 million versus ₽242.628 million a year earlier.
05.04.2022
IMCB's RAS net income for 2021 was ₽129.17 million, up 4.2% from ₽123.909 million in the previous year. Revenue increased 9.6% to ₽265.889 million versus ₽242.628 million a year earlier.
General information
Company nameIMCB
Tags#biotechnology, #stem cells
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressgorod Moskva
Mailing address119333, g. Moskva, ul. Gubkina, d. 3, korp. 1, etazh 1, pom. 1, komn. 24
CEOPrihodko Aleksandr Viktorovich
Phone+7(495) 646-80-76
Websiteinvest.gemabank.ru
Information disclosuree-disclosure.ru